---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004109"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:32:15.775199+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alnylam reports preliminary FY2022 net product revenue of $894M, up 35% YoY

## Summary
- ONPATTRO: Q4 $122M, FY $558M; AMVUTTRA: Q4 $69M, FY $94M; combined TTR revenue grew 37% YoY.
- GIVLAARI: Q4 $47M, FY $173M (+35% YoY); OXLUMO: Q4 $24M, FY $70M (+17% YoY).
- Year-end cash and marketable securities ~$2.2B, down from $2.4B at end 2021.
- Over 2,975 patients on commercial TTR drugs and over 520 on GIVLAARI; 280 on OXLUMO as of year-end.
- Management cites strong AMVUTTRA launch and reiterates Alnylam P5x25 strategic goals.

## SEC filing metadata
- accession: 0001193125-23-004109
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/0001193125-23-004109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004109
- JSON: https://secwatch.observer/filing/0001193125-23-004109.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004109.txt

## Key facts
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported fourth quarter and full year 2022 results: revenue approximately $262 million and $894 million, respectively.
  - Period: fourth quarter and full year 2022
  - Revenue: approximately $262 million and $894 million, respectively
  - Result: preliminary results
  source text: On January 8, 2023, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2022 global net product revenues of approximately $262 million and $894 million, respectively, for ONPATTRO ® (patisiran), AMVUTTRA ® (vutrisiran), GIVLAARI ® (givosiran) and OXLUMO ® (lumasiran), and provided additional updates on the products’ commercial launches.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/0001193125-23-004109-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.